Author/Authors :
Akihiko Nishikimi، نويسنده , , Takehito Uruno، نويسنده , , Xuefeng Duan، نويسنده , , Qinhong Cao، نويسنده , , Yuji Okamura، نويسنده , , Takashi Saitoh، نويسنده , , Nae Saito، نويسنده , , Shunsuke Sakaoka، نويسنده , , Yao Du، نويسنده , , Atsushi Suenaga، نويسنده , , Mutsuko Kukimoto-Niino، نويسنده , , Kei Miyano، نويسنده , , Kazuhito Gotoh، نويسنده , , Takayoshi Okabe، نويسنده , , Fumiyuki Sanematsu، نويسنده , , Yoshihiko Tanaka، نويسنده , , Hi، نويسنده ,
Abstract :
Tissue infiltration of activated lymphocytes is a hallmark of transplant rejection and organ-specific autoimmune diseases. Migration and activation of lymphocytes depend on DOCK2, an atypical Rac activator predominantly expressed in hematopoietic cells. Although DOCK2 does not contain Dbl homology domain typically found in guanine nucleotide exchange factors, DOCK2 mediates the GTP-GDP exchange reaction for Rac through its DHR-2 domain. Here, we have identified 4-[3′-(2″-chlorophenyl)-2′-propen-1′-ylidene]-1-phenyl-3,5-pyrazolidinedione (CPYPP) as a small-molecule inhibitor of DOCK2. CPYPP bound to DOCK2 DHR-2 domain in a reversible manner and inhibited its catalytic activity in vitro. When lymphocytes were treated with CPYPP, both chemokine receptor- and antigen receptor-mediated Rac activation were blocked, resulting in marked reduction of chemotactic response and T cell activation. These results provide a rational of and a chemical scaffold for development of the DOCK2-targeting immunosuppressant.
